Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALF402
- Development stage
- Preclinical
- Lead developer
- Allife Medical Science and Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ALF402 is an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy being developed by Allife Medical Science and Technology. As an iPSC-NK product, it is designed to provide a standardized, "off-the-shelf" cell therapy source, overcoming the limitations of donor-derived NK cells. The mechanism of action involves the direct recognition and lysis of malignant cells through natural cytotoxicity receptors and the release of cytotoxic granules containing perforin and granzymes. ALF402 is currently in preclinical development for the treatment of solid tumors, specifically non-small cell lung cancer (NSCLC), including lung adenocarcinoma, and liver cancer.
Beyond the preview
Go deeper on ALF402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALF402.